| Hazard Information | Back Directory | [Uses]
Vorsetuzumab mafodotin (SGN-75) is an Auristatin-based anti-CD70 antibody-drug conjugate (ADC). Vorsetuzumab mafodotin consists of a humanized monoclonal antibody, Vorsetuzumab and an ADC cytotoxin MMAF. Vorsetuzumab mafodotin has antineoplastic activity[1]. | [in vivo]
Vorsetuzumab mafodotin (SGN-75; 3?mg/kg; four intraperitoneal injections at 4-day interval) significantly reduces median tumour volumes and delays tumour growth[1]. | Animal Model: | Nude (nu/nu) female mice injected with MiaPaCa-2/CD70 tumour pieces[1] | | Dosage: | 3?mg/kg | | Administration: | Intraperitoneal injection; every 4 days; for a total of four doses | | Result: | Significantly reduced median tumour volumes and delayed tumour growth. |
| [References]
[1] M C Ryan, et al. Targeting pancreatic and ovarian carcinomas using the auristatin-based anti-CD70 antibody-drug conjugate SGN-75. Br J Cancer. 2010 Aug 24;103(5):676-84. DOI:10.1038/sj.bjc.6605816 |
|
| Company Name: |
bioleaper
|
| Tel: |
4000880777 17585207275 |
| Website: |
www.bioleaper.com/ |
|